vs
Assertio Holdings, Inc.（ASRT）与Simulations Plus, Inc.（SLP）财务数据对比。点击上方公司名可切换其他公司
Simulations Plus, Inc.的季度营收约是Assertio Holdings, Inc.的1.4倍（$18.4M vs $13.5M），Simulations Plus, Inc.同比增速更快（-2.7% vs -57.9%），过去两年Simulations Plus, Inc.的营收复合增速更高（0.3% vs -35.4%）
Assertio Therapeutics是一家美国专业制药企业，主要聚焦神经病学、疼痛以及中枢神经系统疾病领域的产品销售与推广。公司前身Depomed成立于1995年，总部位于加利福尼亚州纽瓦克，拥有多款获美国FDA批准的产品，目前在纳斯达克上市。
Simulations Plus公司为医药生物、化工、化妆品、食品原料及除草剂领域开发ADMET（吸收、分布、代谢、排泄和毒性）建模仿真软件，并于2014年9月收购了提供临床试验数据分析及咨询服务的Cognigen公司，助力相关行业研发工作开展。
ASRT vs SLP — 直观对比
营收规模更大
SLP
是对方的1.4倍
$13.5M
营收增速更快
SLP
高出55.3%
-57.9%
两年增速更快
SLP
近两年复合增速
-35.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.5M | $18.4M |
| 净利润 | — | $676.0K |
| 毛利率 | — | 59.1% |
| 营业利润率 | -86.7% | 3.9% |
| 净利率 | — | 3.7% |
| 营收同比 | -57.9% | -2.7% |
| 净利润同比 | — | 228.2% |
| 每股收益（稀释后） | $-4.54 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASRTSLP
| Q4 25 | $13.5M | $18.4M | ||
| Q3 25 | $49.5M | $17.5M | ||
| Q2 25 | $29.2M | $20.4M | ||
| Q1 25 | $26.5M | $22.4M | ||
| Q4 24 | $32.2M | $18.9M | ||
| Q3 24 | $29.2M | $18.7M | ||
| Q2 24 | $31.1M | $18.5M | ||
| Q1 24 | $32.4M | $18.3M |
净利润ASRTSLP
| Q4 25 | — | $676.0K | ||
| Q3 25 | $11.4M | $-681.0K | ||
| Q2 25 | $-16.4M | $-67.3M | ||
| Q1 25 | $-13.5M | $3.1M | ||
| Q4 24 | — | $206.0K | ||
| Q3 24 | $-2.9M | $843.0K | ||
| Q2 24 | $-3.7M | $3.1M | ||
| Q1 24 | $-4.5M | $4.0M |
毛利率ASRTSLP
| Q4 25 | — | 59.1% | ||
| Q3 25 | — | 56.4% | ||
| Q2 25 | — | 64.0% | ||
| Q1 25 | — | 58.5% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 36.6% | ||
| Q2 24 | — | 71.5% | ||
| Q1 24 | — | 72.2% |
营业利润率ASRTSLP
| Q4 25 | -86.7% | 3.9% | ||
| Q3 25 | 23.2% | 3.8% | ||
| Q2 25 | -27.5% | -364.5% | ||
| Q1 25 | -50.0% | 12.1% | ||
| Q4 24 | -41.9% | 0.7% | ||
| Q3 24 | -10.4% | -6.2% | ||
| Q2 24 | -11.6% | 10.1% | ||
| Q1 24 | -13.4% | 24.3% |
净利率ASRTSLP
| Q4 25 | — | 3.7% | ||
| Q3 25 | 23.1% | -3.9% | ||
| Q2 25 | -56.0% | -330.6% | ||
| Q1 25 | -51.1% | 13.7% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | -10.0% | 4.5% | ||
| Q2 24 | -11.8% | 16.9% | ||
| Q1 24 | -13.9% | 22.0% |
每股收益（稀释后）ASRTSLP
| Q4 25 | $-4.54 | $0.03 | ||
| Q3 25 | $0.11 | $-0.03 | ||
| Q2 25 | $-0.17 | $-3.35 | ||
| Q1 25 | $-0.14 | $0.15 | ||
| Q4 24 | $-3.28 | $0.01 | ||
| Q3 24 | $-0.03 | $0.04 | ||
| Q2 24 | $-0.04 | $0.15 | ||
| Q1 24 | $-0.05 | $0.20 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.4M | $35.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $94.0M | $127.1M |
| 总资产 | $267.0M | $137.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASRTSLP
| Q4 25 | $63.4M | $35.7M | ||
| Q3 25 | $93.4M | $32.4M | ||
| Q2 25 | $98.2M | $28.4M | ||
| Q1 25 | $87.3M | $21.4M | ||
| Q4 24 | $100.1M | $18.2M | ||
| Q3 24 | $88.6M | $20.3M | ||
| Q2 24 | $88.4M | $119.0M | ||
| Q1 24 | $80.7M | $108.5M |
总债务ASRTSLP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
股东权益ASRTSLP
| Q4 25 | $94.0M | $127.1M | ||
| Q3 25 | $105.8M | $124.8M | ||
| Q2 25 | $93.3M | $123.8M | ||
| Q1 25 | $108.5M | $189.5M | ||
| Q4 24 | $121.1M | $184.7M | ||
| Q3 24 | $130.5M | $182.4M | ||
| Q2 24 | $132.2M | $180.9M | ||
| Q1 24 | $134.5M | $177.0M |
总资产ASRTSLP
| Q4 25 | $267.0M | $137.8M | ||
| Q3 25 | $319.8M | $131.9M | ||
| Q2 25 | $273.8M | $134.4M | ||
| Q1 25 | $286.4M | $201.4M | ||
| Q4 24 | $284.7M | $196.9M | ||
| Q3 24 | $276.0M | $196.6M | ||
| Q2 24 | $279.4M | $192.7M | ||
| Q1 24 | $282.0M | $194.0M |
负债/权益比ASRTSLP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-30.0M | $4.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | 6.26× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASRTSLP
| Q4 25 | $-30.0M | $4.2M | ||
| Q3 25 | $-4.8M | $5.6M | ||
| Q2 25 | $19.1M | $8.1M | ||
| Q1 25 | $-12.5M | $5.7M | ||
| Q4 24 | $11.5M | $-1.3M | ||
| Q3 24 | $-35.0K | $1.7M | ||
| Q2 24 | $7.4M | $5.7M | ||
| Q1 24 | $7.5M | $5.8M |
自由现金流ASRTSLP
| Q4 25 | — | — | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $5.6M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $5.6M | ||
| Q1 24 | — | $5.4M |
自由现金流率ASRTSLP
| Q4 25 | — | — | ||
| Q3 25 | — | 30.5% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 25.0% | ||
| Q4 24 | — | -7.2% | ||
| Q3 24 | — | 8.8% | ||
| Q2 24 | — | 30.0% | ||
| Q1 24 | — | 29.4% |
资本支出强度ASRTSLP
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 2.4% |
现金转化率ASRTSLP
| Q4 25 | — | 6.26× | ||
| Q3 25 | -0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.84× | ||
| Q4 24 | — | -6.18× | ||
| Q3 24 | — | 1.97× | ||
| Q2 24 | — | 1.81× | ||
| Q1 24 | — | 1.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
SLP
| Services Segment | $9.5M | 52% |
| Development | $7.2M | 39% |
| Discovery | $1.3M | 7% |
